Baidu
map

JACC:左房扩大可预测二尖瓣反流患者预后

2019-09-04 不详 MedSci原创

左房扩大在退行性二尖瓣反流(DMR)患者中比较常见,但其与临床预后的联系尚未被证实。本研究的目的旨在评估临床上常规测量左房容积指数(LAVI)是否与DMR患者生存率呈独立相关性。本研究纳入分析了5769名DMR患者(平均年龄63±16岁,女性占47%)。结果发现,患者的LVAI分布广泛(3154名患者的LVAI<40 ml/m2,1606名患者的LVAI为40-59 ml/m2,1009名患

左房扩大在退行性二尖瓣反流(DMR)患者中比较常见,但其与临床预后的联系尚未被证实。本研究的目的旨在评估临床上常规测量左房容积指数(LAVI)是否与DMR患者生存率呈独立相关性。

本研究纳入分析了5769名DMR患者(平均年龄63±16岁,女性占47%)。结果发现,患者的LVAI分布广泛(3154名患者的LVAI<40 ml/m2,1606名患者的LVAI为40-59 ml/m2,1009名患者的LVAI≥60 ml/m2),经过平均10年时间的随访,发现患者的整体生存率与LAVI呈强相关( p < 0.0001)。经药物治疗后的死亡率也明显受LAVI的影响( p < 0.0001)。样条曲线分析中的超额死亡率LAVI的阈值约为40 ml/m2。另外,二尖瓣手术可以明显提高患者的生存率,且仍与LAVI呈中度相关性。

研究结果显示,由左房容积指数测量出的左房扩大与退行性二尖瓣反流患者的生存率明显相关,因此,LVAI应纳入为临床常规对DMR患者测量的项目。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854497, encodeId=f9c6185449e02, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 05 14:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692072, encodeId=987d16920e289, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 26 00:01:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326322, encodeId=3d191326322c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463260, encodeId=47831463260da, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571658, encodeId=4fe115e165823, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
    2019-09-05 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854497, encodeId=f9c6185449e02, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 05 14:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692072, encodeId=987d16920e289, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 26 00:01:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326322, encodeId=3d191326322c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463260, encodeId=47831463260da, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571658, encodeId=4fe115e165823, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854497, encodeId=f9c6185449e02, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 05 14:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692072, encodeId=987d16920e289, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 26 00:01:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326322, encodeId=3d191326322c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463260, encodeId=47831463260da, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571658, encodeId=4fe115e165823, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854497, encodeId=f9c6185449e02, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 05 14:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692072, encodeId=987d16920e289, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 26 00:01:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326322, encodeId=3d191326322c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463260, encodeId=47831463260da, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571658, encodeId=4fe115e165823, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
    2019-09-06 wwzzly
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854497, encodeId=f9c6185449e02, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Sep 05 14:01:00 CST 2019, time=2019-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692072, encodeId=987d16920e289, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Jul 26 00:01:00 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326322, encodeId=3d191326322c2, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463260, encodeId=47831463260da, content=<a href='/topic/show?id=cff92389310' target=_blank style='color:#2F92EE;'>#二尖瓣#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23893, encryptionId=cff92389310, topicName=二尖瓣)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fdb26536308, createdName=wwzzly, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571658, encodeId=4fe115e165823, content=<a href='/topic/show?id=41e33e76137' target=_blank style='color:#2F92EE;'>#反流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37761, encryptionId=41e33e76137, topicName=反流)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=220d15750403, createdName=feifers, createdTime=Fri Sep 06 05:01:00 CST 2019, time=2019-09-06, status=1, ipAttribution=)]
    2019-09-06 feifers

相关资讯

JACC:急性心梗患者不良预后事件的预测研究

目前,对于疑似有急性心梗(AMI)患者进行早期及准确的主要不良事件(MACE)的评估尚未达到临床要求。本研究提出假设:将临床判断和心电图联合高敏心脏肌钙蛋白(hs-cTn)的检测可以进一步提高MACE的预测效果。本研究纳入了急症疑似有AMI的患者,主要终点事件是MACE,包括全因死亡、心脏猝死、AMI、心源性休克、持续性室性心律失常和房室传导阻滞。次要终点事件是MACE+接受早期血运重建的不稳定性

JACC:颈总动脉滤过器的置入可预防房颤患者的卒中发生

不适于口服抗凝药(OACs)的卒中和房颤高风险患者需要其他的卒中预防策略,一种新型的永久性线圈过滤器可以直接置入两个颈总动脉(CCA),用于捕获直径大于1.4 mm的栓塞。本CAPTURE临床试验研究的目的旨在评估置入两边CCA滤过器的可行性和安全性。本研究的患者纳入标准为:房颤患者,CHA2DS2-VASc评分≥2分,OAC不适用,CCA直径为4.8-9.8mm,且没有颈动脉狭窄>30%。经超声

Eur Heart J:韩国50万人研究,有心血管病者更应该活动

近期,ESC上发布的一项对近50万人的韩国研究发现,有心血管病的人比健康人从身体活动中获益更多,该研究同期发表在《欧洲心脏杂志》上。

中国ACS患者血脂管理的现状与挑战

为进一步优化中国急性冠脉综合征(Acute coronary syndrome,ACS)患者全程管理,尤其是其长期血脂管理。2019欧洲心脏病学会(ESC)年会期间来自中国的三位心血管病学专家:北京大学第一医院霍勇教授、复旦大学中山医院葛均波院士以及中国人民解放军总医院陈韵岱教授与多位欧洲专家共同参与了“中欧ACS标准化管理学术交流启动会”。三位专家在会上也对中国ACS患者全程管理,尤其是血脂管理

JACC:经胎盘药物治疗胎儿快速心律失常的安全性和可行性研究

胎儿快速心律失常的治疗尚没有统一标准。本研究的目的旨在评估经胎盘治疗胎儿室上性心动过速(SVT)和心房扑动(AFL)的有效性和安全性。本研究通过地高辛、索他洛尔和氟卡尼经胎盘对22-37孕周的单胎妊娠的SVT和AFL≥180次/分钟胎儿进行治疗,主要终点事件是胎儿快速心律失常的解决,次要终点事件是胎死、早产和新生儿心律失常。最终,共纳入了来自15个日本医学中心的50名患者,其中短室房SVT胎儿有1

2019 ESC:达格列净显著降低心血管死亡和心力衰竭恶化风险

2019年9月1日,阿斯利康公布了达格列净III期研究DAPA-HF的结果,这一研究结果具有里程碑意义。该研究结果显示,达格列净在标准治疗的基础上,可以显著降低心血管死亡和心力衰竭恶化风险。DAPA-HF是首个在伴或不伴2型糖尿病的射血分数降低心衰患者(HFrEF)中应用SGLT2抑制剂治疗的心衰结局研究。达格列净目前被批准用于2型糖尿病患者的治疗。2019年8月公布的topline结果显示DAP

Baidu
map
Baidu
map
Baidu
map